profit from every $100 of sales.
$0$100
Exact Sciences
We have no price for Exact Sciences since 23 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$104.91+0.00% today
+76.4% since Oct 9, 25
1-year low $58.341-year high $104.91
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Exact Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Exact Sciences | No profit yet | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Exact Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- 582.8×
- –
- 8.3×
- 6.2×
- 56.1×
- 397.4×
- 1.8%
- -1.0%
- 0.0%
Profitability
- 69.7%
- -6.2%
- -6.4%
- 1.7%
- -4.1%
- -9.9%
- -8.5%
- -3.5%
- -3.8%
- 16.1%
Growth
- +16.4%
- –
- +378.6%
- –
- +2.4%
Financial health
- 28.8×
- 1.05
- 43.0%
- -5.5×
- 2.23
- 1.97
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 952
Bottom 17%of 883
Top 35%of 870
Top 45%of 985
What analysts expect
- Average price target
- $105.00
- Range
- $105.00 – $105.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 13, 2026 | -0.45 | -0.11 | −316.9% |
| Nov 3, 2025 | 0.24 | -0.06 | +492.0% |
| Aug 6, 2025 | 0.22 | -0.02 | +1,200.0% |
| May 1, 2025 | -0.21 | -0.37 | +43.2% |
| Feb 19, 2025 | -0.06 | -0.29 | +79.3% |
| Nov 5, 2024 | -0.21 | -0.20 | −7.2% |
| Jul 31, 2024 | -0.09 | -0.37 | +75.7% |
| May 8, 2024 | -0.50 | -0.47 | −5.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
27No pass
Philip Fisher
38No pass
Peter Lynch
47No pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
24No pass
Questions about Exact Sciences
Is Exact Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Exact Sciences AI analysis
What does Exact Sciences do?
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. It is in Medical - Diagnostics & Research.
Does Exact Sciences pay a dividend?
No. Exact Sciences does not pay a dividend at the moment.
Is Exact Sciences stock halal?
Yes. Exact Sciences passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
Who are Exact Sciences's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Exact Sciences's.
Prices: daily closes to Mar 23, 2026. Fundamentals: company reports via invest-like data.